Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial
LIVONIA, Mich., June 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line dataset from the investigator-led Phase 2a study of adult FPLD …